Effect of Omega 3 Enriched Oral Nutritional Supplement on Nutritional Status of CRC and NSCLC Patients

Inclusion criteria

• Histologically proven CRC or histologically or cytologically proven NSCLC
• Eligible and scheduled for at least 2 cycles of 4-week cycles of systemic treatment, 3 cycles of 3-week cycles of systemic treatment or 4 cycles of 2-week cycles of systemic treatment
• At risk of malnutrition or malnourished [PG-SGA-SF > 4]
• Performance status ECOG 0 or 1
• Weight loss grade 0-3 according to Martin et al1
• <11% weight loss in the past 6 months
• Age ≥ 18 years
• Written informed consent

Exclusion criteria

• Presence of ileostoma or ileal pouch
• GI-related or major surgery in 30 days prior to baseline
• Severe hypercalcemia, i.e. total calcium level, corrected for albumin ≥ 14.0 mg/dL (3.5 mmol/L)
• Use of ONS, enteral nutrition or parenteral nutrition within 14 days prior to entry into the study
• Use of fish oil containing supplements, within 30 days prior to entry into the study or expected to use this during the study
• Use of more than 200 iU/day of vitamin D containing supplements within 30 days prior to entry into the study or expected to use this during the study
• Life expectancy of < 3 months
• Severe renal dysfunction (<29 ml/min/1.73m2 eGRF or albumin:creatinine (ACR) > 30) or hepatic encephalopathy
• Allergy to cow's milk protein or fish, known protein sensitivity or suffering galactosemia
• Known pregnancy or lactation
• Current alcohol or drug abuse in opinion of the investigator
• Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements
• Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study